{"id":"NCT03536949","sponsor":"RVL Pharmaceuticals, Inc.","briefTitle":"Study of Safety of RVL-1201 in Treatment of Blepharoptosis","officialTitle":"A Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Safety of RVL-1201 in the Treatment of Acquired Blepharoptosis (Study RVL-1201-203)","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2018-06-20","primaryCompletion":"2019-03-14","completion":"2019-03-27","firstPosted":"2018-05-25","resultsPosted":"2020-09-16","lastUpdate":"2020-09-16"},"enrollment":234,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"TRIPLE","primaryPurpose":"TREATMENT"},"conditions":["Blepharoptosis"],"interventions":[{"type":"DRUG","name":"RVL-1201","otherNames":[]},{"type":"OTHER","name":"Vehicle ophthalmic solution","otherNames":[]}],"arms":[{"label":"RVL-1201 Ophthalmic Solution, 0.1%","type":"EXPERIMENTAL"},{"label":"Vehicle ophthalmic solution","type":"PLACEBO_COMPARATOR"}],"summary":"Phase 3 study to evaluate the extended safety of RVL-1201 compared to placebo for treatment of blepharoptosis. Eligible subjects will be randomized to one of 2 treatment arms.","primaryOutcome":{"measure":"Mean Change From Baseline in Intraocular Pressure (IOP) at Day 84","timeFrame":"Screening/Day 1 to Day 84","effectByArm":[{"arm":"RVL-1201 Ophthalmic Solution, 0.1%","deltaMin":-0.6,"sd":2.4},{"arm":"Vehicle Ophthalmic Solution","deltaMin":-0.2,"sd":2.52}],"pValues":[]},"eligibility":{"minAge":"9 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":35,"countries":["United States"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":2,"n":157},"commonTop":["Dry eye","Vital dye staining cornea present","Headache","Conjunctival hyperaemia","Nasopharyngitis"]}}